Publications by authors named "A Balaton"
Objectives: To evaluate a new US Food and Drug Administration (FDA)-cleared immunohistochemistry (IHC) control (IHControls [Boston Cell Standards]) comprising peptide epitopes for HER2, estrogen receptor (ER), and progesterone receptor (PR) attached to cell-sized microspheres and to compare its performance against conventional tissue controls.
Methods: IHControls and tissue/cell line controls for HER2, ER, and PR were compared side by side daily at 5 clinical IHC laboratories for 1 to 2 months. Separately, the sensitivity of the 2 types of controls was evaluated in simulated IHC assay failure experiments by diluting the primary antibody.
Background: Symptomatic parapelvic cysts (PPC) are rare entities. Our objective is to highlight specific features of PPC to avoid a misdiagnosis of UPJ obstruction.
Methods: We retrospectively reviewed the records of children managed between 2012-2017.
Graves' orbitopathy might be severe, requiring treatment with high-dose glucocorticoids. A lytic bone lesion, malignant lesions, and diseases resulting from bone remodeling processes (eg, Paget's disease) must be excluded by markers and imagery. Outcomes of high-dose glucocorticoids and thyrotoxicosis must be screened and prevented.
View Article and Find Full Text PDFImpact of country of birth on genetic testing of metastatic lung adenocarcinomas in France: African women exhibit a mutational spectrum more similar to Asians than to Caucasians.
Oncotarget
August 2017
Article Synopsis
- The study aimed to assess the prevalence of oncogenic driver mutations in lung adenocarcinoma patients, particularly among Caucasian populations in France, utilizing a standardized molecular testing method.
- Out of 2,219 patients studied, various mutations were found at differing rates, with notable differences in mutation prevalence based on ethnicity, especially showing higher rates of targetable mutations in African women.
- The results indicate that genetic testing in clinical practice can identify specific patient subsets by ethnicity that may benefit from targeted therapies, highlighting the importance of personalized medicine in oncology.
Clusterin (CLU) is a sulfated glycoprotein implicated in many physiological and pathological processes, including tumorigenesis. Several studies have reported the overexpression of CLU in human neoplasm, examined by immunohistochemistry. However, there are no extensive data on its role in the thyroid.
View Article and Find Full Text PDF